Shanghai Haohai Biological Technology Co., Ltd. provided consolidated earnings guidance for the six months ended 30 June 2023. For the period, the company expects to record an unaudited net profit attributable to shareholders of the Company of approximately RMB180,000,000.00 to RMB220,000,000.00 during the Reporting Period, representing an increase of approximately RMB108,970,000.00 to RMB148,970,000.00, or approximately 153.41% to 209.73%, as compared to that in 2022 (corresponding period in 2022: unaudited net profit attributable to shareholders of the Company of RMB71,029,961.51). The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB162,000,000.00 to RMB202,000,000.00, representing an increase of approximately RMB108,809,400.00 to RMB148,809,400.00, or approximately 204.57% to 279.77%, as compared to that in 2022 (corresponding period in 2022: unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss of RMB53,190,598.27).